Drugs in ATC Class N07BC

Up to Top Level ATC Classes

Up to N - Nervous system

Up to N07 - OTHER NERVOUS SYSTEM DRUGS

Up to N07B - DRUGS USED IN ADDICTIVE DISORDERS

Drugs in ATC Class: N07BC - Drugs used in opioid dependence

Tradename	Generic Name
BRIXADI	buprenorphine
BUPRENORPHINE	buprenorphine
BUTRANS	buprenorphine
SUBLOCADE	buprenorphine

N07BC Market Analysis and Financial Projection

The market for ATC Class N07BC drugs (used in opioid dependence) is experiencing rapid growth driven by the escalating opioid crisis and innovation in treatment modalities. Here's an analysis of the market dynamics and patent landscape:

---

Market Dynamics

Expanding Market Size

• The global opioid use disorder (OUD) treatment market is projected to grow from USD 5.78 billion in 2024 to USD 10.77 billion by 2032 (8.1% CAGR)[3]. Alternative estimates forecast even steeper growth, reaching USD 8.8 billion by 2034 (9.9% CAGR)[8][16].
• Key drivers include rising opioid addiction rates, increased adoption of medication-assisted treatment (MAT) like buprenorphine and methadone, and government initiatives to expand access to care[3][12].

Dominant Drug Classes

1. Buprenorphine

   • Leads market share due to its partial agonist properties, reducing cravings without inducing euphoria. It accounted for over 1.3 million U.S. prescriptions in 2019[12].
   • New formulations (e.g., sublingual films, implants) and combination therapies (e.g., buprenorphine/naloxone) enhance adherence and safety[10][17].

2. Methadone

   • Remains critical for long-term maintenance, though its use is often restricted to specialized clinics[3].

3. Naloxone

   • Demand for overdose-reversal agents is surging, with innovations like nasal sprays and experimental enhancers (e.g., negative allosteric modulators) improving efficacy[14].

Regional Trends

• North America dominates (56% market share)[12], driven by high opioid addiction rates and funding for MAT programs.
• Asia-Pacific is the fastest-growing region (projected 39% revenue share by 2037)[12], fueled by expanding access to opioid replacement therapies in countries like India and Thailand.

---

Patent Landscape

Key Innovations

• Buprenorphine Formulations

  • Purdue Pharma patented a fast-dissolving buprenorphine wafer (dissolves in seconds)[5].
  • Indivior and others hold patents for sublingual films and monthly injectables (e.g., Sublocade)[9][17].

• Naloxone Enhancers

  • Researchers developed compounds like NAM-368 to extend naloxone’s binding to opioid receptors, potentially reducing required doses by 90%[14].

• Novel Delivery Systems

  • Patents cover implantable buprenorphine devices (lasting 6–12 months) and abuse-deterrent transdermal patches[9][17].

Evergreening Strategies

• Pharmaceutical companies frequently extend market exclusivity through patent thickets (e.g., AstraZeneca secured 90+ years of protections for six drugs)[11].
• Johnson & Johnson’s HIV drug Prezista illustrates this trend, with 167 patent protections delaying generics for 16 years[11].

Legal Challenges

• Purdue Pharma faced lawsuits over its role in the opioid crisis but continued patenting addiction treatments (e.g., its rapid-release buprenorphine wafer)[5].
• Patent litigation and FDA orange book disputes remain common, particularly around abuse-deterrent formulations[9][11].

---

Competitive Landscape

• Top Players: Alkermes (Vivitrol), Indivior (Sublocade), Teva, and Titan Pharmaceuticals lead the market[12][17].
• Strategic Moves:
  • Partnerships to expand access (e.g., Indivior-Alvogen collaboration for sublingual films)[17].
  • Investment in telemedicine platforms to deliver MAT in underserved regions[16].

---

Challenges and Opportunities

• Barriers: Stigma, regulatory hurdles for methadone, and high costs of newer therapies (e.g., implantable buprenorphine).
• Opportunities: Development of dual-acting drugs (e.g., vaccines targeting opioid receptors)[4][14] and expansion of low-cost generics in emerging markets[12].

---

The N07BC drug market is poised for sustained growth, shaped by innovation in formulations, patent strategies, and global efforts to combat opioid addiction. However, balancing affordability with R&D incentives remains critical to addressing this public health crisis.

References

1. https://www.unsw.edu.au/content/dam/images/medicine-health/ndarc/2022-08-ndarc-reports/2024-04-Cryptomarketmethods_Sep2023.pdf
2. https://patents.justia.com/patent/10675278
3. https://www.databridgemarketresearch.com/reports/global-opioid-use-disorder-market
4. https://patents.google.com/patent/US20140093525A1/en
5. https://www.cbsnews.com/news/oxycontin-maker-receives-patent-for-drug-to-treat-opioid-addiction/
6. https://en.wikipedia.org/wiki/ATC_code_N07
7. https://www.cda-amc.ca/sites/default/files/hta-he/HC0064_OAT%20Utilization%20Analysis.pdf
8. https://www.globenewswire.com/news-release/2025/02/10/3023560/32656/en/Opioid-Use-Disorders-Market-to-Reach-USD-8-8-Billion-by-2034-Driven-by-Expanding-Addiction-Treatment-Programs-Exclusive-Report-by-Transparency-Market-Research-Inc.html
9. https://pubchem.ncbi.nlm.nih.gov/compound/Buprenorphine
10. https://atcddd.fhi.no/atc_ddd_index/?code=N07BC&showdescription=yes
11. https://www.uclawsf.edu/2020/09/24/patent-drug-database/
12. https://www.researchnester.com/reports/opioid-dependence-treatment-market/4003
13. https://pubchem.ncbi.nlm.nih.gov/compound/5462328
14. https://medicine.washu.edu/news/experimental-drug-supercharges-opioid-overdose-reversal-drug/
15. https://www.aeaweb.org/doi/10.1257/pol.20220699.appx
16. https://www.globenewswire.com/news-release/2025/02/27/3033651/0/en/Opioid-Use-Disorder-Treatment-Market-to-Reach-USD-1-747-0-Million-by-2035-with-7-4-CAGR-Growth-Future-Market-Insights-Inc.html
17. https://www.futuremarketinsights.com/reports/opioid-use-disorder-treatment-market